Sandoz Recalls Ranitidine Capsules Due to NDMA Impurity Detection
Sandoz is recalling Ranitidine Hydrochloride Capsules 300mg because a trace amount of the impurity NDMA was detected.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving significant chemical impurities like NDMA.
Plain-English summary
Sandoz, Inc. is recalling Sandoz Ranitidine Hydrochloride Capsules 300mg (NDC 0781-2865-31). The recall involves 136,788 bottles distributed nationwide in the United States.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA). The affected lots have expiration dates ranging from April 30, 2020, to March 31, 2021.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on alternative treatments or returns.
The recalled product
- Product
- Sandoz Ranitidine Hydrochloride Capsules 300mg 30 Capsules Rx Only Manufactured by Sandoz Inc. Princeton, NJ 08540 Product of India NDC 0781-2865-31
- Manufacturer
- Sandoz, Inc
- Category
- Drug — Prescription Medication
- Affected units
- 136,788
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Sandoz, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Sandoz, Inc
See all →- LowFocalin XR 5mg capsules carry incorrect or missing lot and expiry
FDA (Drugs) · 2026-06-24
- ModerateCyclophosphamide injection vials recalled after a transportation temperature excursion
FDA (Drugs) · 2025-09-24
- ModerateCiprofloxacin and dexamethasone otic suspension recalled following temperature abuse
FDA (Drugs) · 2025-09-17
- SevereBuffered penicillin G potassium vials may actually contain cefazolin for injection
FDA (Drugs) · 2025-07-09
- SevereSandoz cefazolin cartons contained vials labeled as penicillin G potassium
FDA (Drugs) · 2025-07-09
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
Similar recalls
- SevereNovitium Pharma Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2019-11-20
- SevereDr. Reddy's Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2019-11-13
- SevereAppco Pharma Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2020-01-15
- LowSandoz Recalls Dicloxacillin Sodium Capsules Due to Impurity Testing Failures
FDA (Drugs) · 2016-06-29
- SevereDirect Rx Recalls Ranitidine 300 mg Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-10-14
- SevereAvKare Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2019-11-06